Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations

J Clin Oncol. 2020 Dec 10;38(35):4208-4218. doi: 10.1200/JCO.20.00744. Epub 2020 Oct 26.

Authors

Timothy F Burns¹, Hossein Borghaei², Suresh S Ramalingam³, Tony S Mok⁴, Solange Peters⁵

Affiliations

¹ University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA.
² Fox Chase Cancer Center, Philadelphia, PA.
³ Division of Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA.
⁴ State Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong.
⁵ Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / enzymology
Carcinoma, Non-Small-Cell Lung / genetics*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / enzymology
Lung Neoplasms / genetics*
Models, Molecular
Molecular Targeted Therapy
Mutation
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors
Proto-Oncogene Proteins p21(ras) / chemistry
Proto-Oncogene Proteins p21(ras) / genetics*
Proto-Oncogene Proteins p21(ras) / metabolism

Substances

KRAS protein, human
Protein Kinase Inhibitors
Proto-Oncogene Proteins p21(ras)